Evidence map›Paper›PMID 26754847›Full record

ArticleBMC genomics2016

Pangenome-wide and molecular evolution analyses of the Pseudomonas aeruginosa species.

Jeanneth Mosquera-Rendón, Ana M Rada-Bravo, Sonia Cárdenas-Brito, Mauricio Corredor, Eliana Restrepo-Pineda, Alfonso Benítez-Páez

Open access · goldAbstract read
In one paragraph

Article in BMC genomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 107 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. mSphere · 2026
    Article
  7. Article
  8. Article
  9. Predicting Strain-Specific Metabolic Capabilities in the GenusComputational and structural biotechnology journal · 2026
    Article
  10. Article
  11. Article
  12. Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025
    Review
  13. Proteomic landscape of imipenem resistance inFrontiers in cellular and infection microbiology · 2025
    Article
  14. Article
  15. Article
  16. The complete catalog of antimicrobial resistance secondary active transporters inComputational and structural biotechnology journal · 2024
    Article
  17. Article
  18. Review
  19. DecodingFrontiers in cellular and infection microbiology · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jeanneth Mosquera-RendónBioinformatics Analysis Group-GABi, Centro de Investigación y Desarrollo en Biotecnología-CIDBIO, 111221, Bogotá DC, Colombia. jmosquera@cidbio.org.
Ana M Rada-BravoGrupo Bacterias y Cáncer, Universidad de Antioquia, Medellín, Colombia. ana.rada@colmayor.edu.co.
Sonia Cárdenas-BritoBioinformatics Analysis Group-GABi, Centro de Investigación y Desarrollo en Biotecnología-CIDBIO, 111221, Bogotá DC, Colombia. scardenas@cidbio.org.
Mauricio CorredorGrupo GEBIOMIC, FCEN, Universidad de Antioquia, Medellín, Colombia. mauricio.corredor@udea.edu.co.
Eliana Restrepo-PinedaGrupo Bacterias y Cáncer, Universidad de Antioquia, Medellín, Colombia. elianarestrepo.pineda@gmail.com.
Alfonso Benítez-PáezBioinformatics Analysis Group-GABi, Centro de Investigación y Desarrollo en Biotecnología-CIDBIO, 111221, Bogotá DC, Colombia. abenitez@cidbio.org.
Universidad de Antioquia · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDrug treatments and vaccine designs against the opportunistic human pathogen Pseudomonas aeruginosa have multiple issues, all associated with the diverse genetic traits present in this pathogen, ranging from multi-drug resistant genes to the molecular machinery for the biosynthesis of biofilms. Several candidate vaccines against P. aeruginosa have been developed, which target the outer membrane proteins; however, major issues arise when attempting to establish complete protection against this pathogen due to its presumably genotypic variation at the strain level. To shed light on this concern, we proposed this study to assess the P. aeruginosa pangenome and its molecular evolution across multiple strains.

resultsThe P. aeruginosa pangenome was estimated to contain more than 16,000 non-redundant genes, and approximately 15 % of these constituted the core genome. Functional analyses of the accessory genome indicated a wide presence of genetic elements directly associated with pathogenicity. An in-depth molecular evolution analysis revealed the full landscape of selection forces acting on the P. aeruginosa pangenome, in which purifying selection drives evolution in the genome of this human pathogen. We also detected distinctive positive selection in a wide variety of outer membrane proteins, with the data supporting the concept of substantial genetic variation in proteins probably recognized as antigens. Approaching the evolutionary information of genes under extremely positive selection, we designed a new Multi-Locus Sequencing Typing assay for an informative, rapid, and cost-effective genotyping of P. aeruginosa clinical isolates.

conclusionsWe report the unprecedented pangenome characterization of P. aeruginosa on a large scale, which included almost 200 bacterial genomes from one single species and a molecular evolutionary analysis at the pangenome scale. Evolutionary information presented here provides a clear explanation of the issues associated with the use of protein conjugates from pili, flagella, or secretion systems as antigens for vaccine design, which exhibit high genetic variation in terms of non-synonymous substitutions in P. aeruginosa strains.

Indexed as

Evolution, MolecularPhylogenyBiofilmsGenome, BacterialGenotypeHumansPseudomonas aeruginosaPseudomonas Infections

Identifiers

PMID26754847
PMCPMC4710005
OpenAlexW2235699210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.